Lantern Pharma (LTRN) Tops Q2 EPS by 13c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.40), $0.13 better than the analyst estimate of ($0.53).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) PT Lowered to $350 at UBS on Lowered EPS Estimates
• KB Home (KBH) PT Raised to $66 at UBS on Market Stabilisation and Execution